X

Trial Profile

Melphalan flufenamide (melflufen) and Dexamethasone re-induction in Daratumumab-refractory Multiple Myeloma as an Adjunct to Continued Daratumumab (MERMAID)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 28 Dec 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Daratumumab (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Melphalan flufenamide (Primary)
Indications Multiple myeloma
Focus Therapeutic Use
Acronyms MERMAID

Most Recent Events

22 Dec 2021 Status has been changed to discontinued.
29 Jul 2021 Status changed from recruiting to suspended due to the detrimental effect on overall survival of patients in the OCEAN trial, according to a Food and Drug Administration media release
18 May 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com